Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Gossamer Bio, Inc.GOSS · Entity 6928 | Director | June 09, 2022 | July 15, 2022 |
| Sana Biotechnology, Inc.SANA · Entity 4870 | Director | June 04, 2026 | June 05, 2026 |
| ViewRay, Inc.VRAY · Entity 111118 | Director · 10% owner | September 13, 2016 | September 16, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Gossamer Bio, Inc.
Report date June 09, 2022 · Filed July 15, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.02 · Expires 2032-06-08 | Direct | 30,000 |
Reported balance
After 2022-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-09 · Grant · Acquired 30,000 · Balance 30,000 F1: Award made pursuant to Non-Employee Director Compensation Program. F2: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer'sstockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Award made pursuant to Non-Employee Director Compensation Program.
F2: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer'sstockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
Sana Biotechnology, Inc.
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.96 · Expires 2036-06-03 | Direct | 90,000 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 90,000 · Balance 90,000 F1: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.
ViewRay, Inc.
Report date September 13, 2016 · Filed September 16, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,964 |
Reported balance
After 2016-09-13 transaction · row 1
1 source rowRow 1 · 2016-09-13 · Grant · Acquired 18,964 · Balance 18,964 F1: Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon vesting. 100% of the RSUs shall be fully vested as of the date of grant, however, delivery of the shares will be deferred until the earlier of (i) the Reporting Person's termination of service from the Issuer's board of directors or (ii) a Change of Control of the Issuer as defined in the Issuer's 2015 Equity Incentive Award Plan. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 7,461,923 |
Reported balance
Holding disclosure · report date 2016-09-13 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 7,461,923 F2: Shares are held by Aisling Capital II, LP ("Aisling"). Aisling Capital Partners, LP ("Aisling GP"), is the general partner of Aisling. Aisling Capital Partners LLC ("Aisling Parters"), is the general partner of Aisling GP. The individual managing members ("Aisling Managers") of Aisling Partners are Dennis Purcell, Andrew Schiff, M.D. and Steve Elms. Dr. Bilenker, a member of the board of directors of ViewRay, Inc., is an Operating Partner of Aisling Capital, LLC, an affiliate of Aisling, however voting and dispositive decisions with respect to shares held by Aisling are not made by Dr. Bilenker. Dr. Bilenker disclaims beneficial ownership of the shares held by Aisling, except to the extent of any pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon vesting. 100% of the RSUs shall be fully vested as of the date of grant, however, delivery of the shares will be deferred until the earlier of (i) the Reporting Person's termination of service from the Issuer's board of directors or (ii) a Change of Control of the Issuer as defined in the Issuer's 2015 Equity Incentive Award Plan.
F2: Shares are held by Aisling Capital II, LP ("Aisling"). Aisling Capital Partners, LP ("Aisling GP"), is the general partner of Aisling. Aisling Capital Partners LLC ("Aisling Parters"), is the general partner of Aisling GP. The individual managing members ("Aisling Managers") of Aisling Partners are Dennis Purcell, Andrew Schiff, M.D. and Steve Elms. Dr. Bilenker, a member of the board of directors of ViewRay, Inc., is an Operating Partner of Aisling Capital, LLC, an affiliate of Aisling, however voting and dispositive decisions with respect to shares held by Aisling are not made by Dr. Bilenker. Dr. Bilenker disclaims beneficial ownership of the shares held by Aisling, except to the extent of any pecuniary interest therein, if any.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Loxo Oncology, Inc.
Report date February 15, 2019 · Filed February 15, 2019
Section 16 reporting ended · disclosed 2019-02-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 1
1 source rowRow 1 · 2019-02-15 · Disposition to issuer · Disposed 162,707 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. |
| Common StockSEC Table I · non-derivative | IndirectBy Joshua H. Bilenker,ttee Joshua Bilenker 2018 GRAT, dated 06/20/2018 | 0 |
Reported balance
After 2019-02-15 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2019-02-15 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.18 · Expires 2023-11-14 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-02-15 · Disposition to issuer · Disposed 27,459 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.65 · Expires 2024-06-18 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-02-15 · Disposition to issuer · Disposed 64,471 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.67 · Expires 2024-12-18 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-02-15 · Disposition to issuer · Disposed 318,514 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.69 · Expires 2025-12-15 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-02-15 · Disposition to issuer · Disposed 142,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.27 · Expires 2026-12-05 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-02-15 · Disposition to issuer · Disposed 209,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.56 · Expires 2027-03-14 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-02-15 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.88 · Expires 2028-01-03 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-02-15 · Disposition to issuer · Disposed 300,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $139.77 · Expires 2029-01-01 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-02-15 · Disposition to issuer · Disposed 128,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 5, 2026 20:32 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001612312-26-000002 · primarydocument.xml · derivative · entry 1 Bilenker Joshua H. · CIK 0001612312 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2036-06-03 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:40 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001562180-25-004646 · primarydocument.xml · derivative · entry 1 Bilenker Joshua H. · CIK 0001612312 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 5, 2026 and (ii) immediately prior to the 2026 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:21 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 54,278 | $0.00 Strike: $7.36 | $0.00 |
DisclosureSEC source: 0001562180-24-004838 · primarydocument.xml · derivative · entry 1 Bilenker Joshua H. · CIK 0001612312 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,278 Underlying: Common Stock · 54,278 shares Expires 2034-06-05 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. Read SEC document |
| June 06, 2024 Filed Jul 15, 2024 20:08 UTC Amendment | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $7.36 | $0.00 |
DisclosureSEC source: 0001562180-24-005715 · primarydocument.xml · derivative · entry 1 Bilenker Joshua H. · CIK 0001612312 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2034-06-05 F1 · shares: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired. F2 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. F1 · derivative.underlying_shares: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired. F1 · balance_after: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 20:34 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0001562180-23-005030 · primarydocument.xml · derivative · entry 1 Bilenker Joshua H. · CIK 0001612312 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2033-06-07 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 8, 2024 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 8, 2023. Read SEC document |
| June 09, 2022 Filed Jul 15, 2022 21:05 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $7.02 | $0.00 |
DisclosureSEC source: 0001728117-22-000071 · wf-form4_165791912081771.xml · derivative · entry 1 Bilenker Joshua H. · CIK 0001612312 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-06-08 F1 · shares: Award made pursuant to Non-Employee Director Compensation Program. F2 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer'sstockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 22:38 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0001562180-22-004945 · primarydocument.xml · derivative · entry 1 Bilenker Joshua H. · CIK 0001612312 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2032-06-05 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2023 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 6, 2022. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 01:41 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 23,500 | $0.00 Strike: $8.97 | $0.00 |
DisclosureSEC source: 0001728117-21-000068 · wf-form4_162337569513720.xml · derivative · entry 1 Bilenker Joshua H. · CIK 0001612312 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2031-06-08 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 22:18 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $25.00 | $0.00 |
DisclosureSEC source: 0000899243-21-005076 · doc4.xml · derivative · entry 1 Bilenker Joshua H. · CIK 0001612312 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2031-02-02 F1 · derivative.exercise_date: The stock option shall vest and become exercisable in full on February 3, 2022. Read SEC document |
| February 03, 2021 Filed Feb 18, 2021 23:59 UTC Amendment | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 11,795 | $0.00 Strike: $25.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007194 · doc4a.xml · derivative · entry 1 Bilenker Joshua H. · CIK 0001612312 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,795 Underlying: Common Stock · 11,795 shares Expires 2031-02-02 F1 · shares: This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired. F2 · derivative.exercise_date: The stock option shall vest and become exercisable in full on February 3, 2022. F1 · derivative.underlying_shares: This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired. F1 · balance_after: This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired. Read SEC document |
| February 03, 2021 Filed Feb 17, 2023 22:17 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | PurchaseCommon Stock | 20,000 | $25.00 | $500,000.00 |
DisclosureSEC source: 0001562180-23-001518 · primarydocument.xml · nonDerivative · entry 1 Bilenker Joshua H. · CIK 0001612312 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 20:52 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (right to buy) · Derivative | 23,500 | $0.00 Strike: $12.10 | $0.00 |
DisclosureSEC source: 0001209191-20-037635 · doc4.xml · derivative · entry 1 Bilenker Joshua H. · CIK 0001612312 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2030-06-16 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 22:30 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (right to buy) · Derivative | 23,500 | $0.00 Strike: $19.54 | $0.00 |
DisclosureSEC source: 0001209191-19-036209 · doc4.xml · derivative · entry 1 Bilenker Joshua H. · CIK 0001612312 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2029-06-09 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| February 15, 2019 Filed Feb 15, 2019 14:06 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 128,000 | $235.00 Strike: $139.77 | $30,080,000.00 |
DisclosureSEC source: 0001567619-19-004566 · doc1.xml · derivative · entry 10 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 128,000 shares Expires 2029-01-01 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. Read SEC document |
| February 15, 2019 Filed Feb 15, 2019 14:06 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 300,000 | $235.00 Strike: $84.88 | $70,500,000.00 |
DisclosureSEC source: 0001567619-19-004566 · doc1.xml · derivative · entry 9 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires 2028-01-03 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. Read SEC document |
| February 15, 2019 Filed Feb 15, 2019 14:06 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $235.00 Strike: $43.56 | $23,500,000.00 |
DisclosureSEC source: 0001567619-19-004566 · doc1.xml · derivative · entry 8 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2027-03-14 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. Read SEC document |
| February 15, 2019 Filed Feb 15, 2019 14:06 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 209,000 | $235.00 Strike: $26.27 | $49,115,000.00 |
DisclosureSEC source: 0001567619-19-004566 · doc1.xml · derivative · entry 7 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 209,000 shares Expires 2026-12-05 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. Read SEC document |
| February 15, 2019 Filed Feb 15, 2019 14:06 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 142,000 | $235.00 Strike: $31.69 | $33,370,000.00 |
DisclosureSEC source: 0001567619-19-004566 · doc1.xml · derivative · entry 6 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 142,000 shares Expires 2025-12-15 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. Read SEC document |
| February 15, 2019 Filed Feb 15, 2019 14:06 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 318,514 | $235.00 Strike: $13.67 | $74,850,790.00 |
DisclosureSEC source: 0001567619-19-004566 · doc1.xml · derivative · entry 5 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 318,514 shares Expires 2024-12-18 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. Read SEC document |
| February 15, 2019 Filed Feb 15, 2019 14:06 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 64,471 | $235.00 Strike: $3.65 | $15,150,685.00 |
DisclosureSEC source: 0001567619-19-004566 · doc1.xml · derivative · entry 4 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 64,471 shares Expires 2024-06-18 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. Read SEC document |
| February 15, 2019 Filed Feb 15, 2019 14:06 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 27,459 | $235.00 Strike: $1.18 | $6,452,865.00 |
DisclosureSEC source: 0001567619-19-004566 · doc1.xml · derivative · entry 3 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,459 shares Expires 2023-11-14 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. Read SEC document |
| February 15, 2019 Filed Feb 15, 2019 14:06 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Disposition to issuerCommon Stock | 30,000 | $235.00 | $7,050,000.00 |
DisclosureSEC source: 0001567619-19-004566 · doc1.xml · nonDerivative · entry 2 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Joshua H. Bilenker,ttee Joshua Bilenker 2018 GRAT, dated 06/20/2018 Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. Read SEC document |
| February 15, 2019 Filed Feb 15, 2019 14:06 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Disposition to issuerCommon Stock | 162,707 | $235.00 | $38,236,145.00 |
DisclosureSEC source: 0001567619-19-004566 · doc1.xml · nonDerivative · entry 1 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. Read SEC document |
| January 02, 2019 Filed Jan 2, 2019 22:03 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | GrantEmployee Stock Option (Right to Buy) · Derivative | 128,000 | $0.00 Strike: $139.77 | $0.00 |
DisclosureSEC source: 0001567619-19-000101 · doc1.xml · derivative · entry 1 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,000 Underlying: Common Stock · 128,000 shares Expires 2029-01-01 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 1/48th of the total number of shares on February 2, 2019, then an additional 1/48th vests on each monthly anniversary thereafter, until such time as the option is 100% vested, subject to the reporting person's continued service through each vesting date. Read SEC document |
| December 11, 2018 Filed Dec 12, 2018 22:12 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $13.67 | $0.00 |
DisclosureSEC source: 0001567619-18-007783 · doc1.xml · derivative · entry 19 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,514 Underlying: Common Stock · 10,000 shares Expires 2024-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F15 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the vesting commencement date, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| December 11, 2018 Filed Dec 12, 2018 22:12 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 100 | $140.61 | $14,061.00 |
DisclosureSEC source: 0001567619-18-007783 · doc1.xml · nonDerivative · entry 16 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,407 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 11, 2018 Filed Dec 12, 2018 22:12 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 1,200 | $140.15 | $168,180.00 |
DisclosureSEC source: 0001567619-18-007783 · doc1.xml · nonDerivative · entry 15 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,507 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F14 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.59 to $140.57 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 11, 2018 Filed Dec 12, 2018 22:12 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 1,100 | $139.05 | $152,955.00 |
DisclosureSEC source: 0001567619-18-007783 · doc1.xml · nonDerivative · entry 14 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,707 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F13 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.53 to $139.40 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 11, 2018 Filed Dec 12, 2018 22:12 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 2,407 | $137.63 | $331,275.41 |
DisclosureSEC source: 0001567619-18-007783 · doc1.xml · nonDerivative · entry 13 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,807 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F12 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.32 to $138.05 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 11, 2018 Filed Dec 12, 2018 22:12 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 3,393 | $136.79 | $464,128.47 |
DisclosureSEC source: 0001567619-18-007783 · doc1.xml · nonDerivative · entry 12 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,214 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F11 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.31 to $137.30 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 11, 2018 Filed Dec 12, 2018 22:12 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 1,153 | $135.76 | $156,531.28 |
DisclosureSEC source: 0001567619-18-007783 · doc1.xml · nonDerivative · entry 11 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,607 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F10 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.30 to $136.28 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 11, 2018 Filed Dec 12, 2018 22:12 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 647 | $134.63 | $87,105.61 |
DisclosureSEC source: 0001567619-18-007783 · doc1.xml · nonDerivative · entry 10 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,760 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F9 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.28 to $135.19 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 11, 2018 Filed Dec 12, 2018 22:12 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionCommon Stock | 10,000 | $13.67 | $136,700.00 |
DisclosureSEC source: 0001567619-18-007783 · doc1.xml · nonDerivative · entry 9 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,407 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 22:12 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $13.67 | $0.00 |
DisclosureSEC source: 0001567619-18-007783 · doc1.xml · derivative · entry 18 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,514 Underlying: Common Stock · 10,000 shares Expires 2024-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F15 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the vesting commencement date, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 22:12 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 100 | $137.39 | $13,739.00 |
DisclosureSEC source: 0001567619-18-007783 · doc1.xml · nonDerivative · entry 8 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,407 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 22:12 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 400 | $136.48 | $54,592.00 |
DisclosureSEC source: 0001567619-18-007783 · doc1.xml · nonDerivative · entry 7 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,507 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F8 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.09 to $136.86 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 22:12 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 2,377 | $135.04 | $320,990.08 |
DisclosureSEC source: 0001567619-18-007783 · doc1.xml · nonDerivative · entry 6 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,907 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.91 to $135.41 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 22:12 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 2,049 | $134.31 | $275,201.19 |
DisclosureSEC source: 0001567619-18-007783 · doc1.xml · nonDerivative · entry 5 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,284 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.91 to $134.83 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 22:12 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 2,104 | $133.00 | $279,832.00 |
DisclosureSEC source: 0001567619-18-007783 · doc1.xml · nonDerivative · entry 4 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,333 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.56 to $133.54 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 22:12 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 2,001 | $132.09 | $264,312.09 |
DisclosureSEC source: 0001567619-18-007783 · doc1.xml · nonDerivative · entry 3 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,437 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.48 to $132.38 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 22:12 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 969 | $130.58 | $126,532.02 |
DisclosureSEC source: 0001567619-18-007783 · doc1.xml · nonDerivative · entry 2 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,438 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.14 to $131.00 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 22:12 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionCommon Stock | 10,000 | $13.67 | $136,700.00 |
DisclosureSEC source: 0001567619-18-007783 · doc1.xml · nonDerivative · entry 1 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,407 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 22:08 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $13.67 | $0.00 |
DisclosureSEC source: 0001567619-18-007046 · doc1.xml · derivative · entry 26 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,514 Underlying: Common Stock · 10,000 shares Expires 2024-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F21 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the vesting commencement date, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 22:08 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 200 | $151.56 | $30,312.00 |
DisclosureSEC source: 0001567619-18-007046 · doc1.xml · nonDerivative · entry 21 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,407 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 22:08 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 400 | $149.25 | $59,700.00 |
DisclosureSEC source: 0001567619-18-007046 · doc1.xml · nonDerivative · entry 20 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,607 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F18 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.99 to $149.71 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 22:08 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 250 | $148.06 | $37,015.00 |
DisclosureSEC source: 0001567619-18-007046 · doc1.xml · nonDerivative · entry 19 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,007 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F17 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.99 to $148.11 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 22:08 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 600 | $147.09 | $88,254.00 |
DisclosureSEC source: 0001567619-18-007046 · doc1.xml · nonDerivative · entry 18 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,257 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F16 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.84 to $147.49 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 22:08 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 700 | $144.61 | $101,227.00 |
DisclosureSEC source: 0001567619-18-007046 · doc1.xml · nonDerivative · entry 17 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,857 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F15 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.14 to $145.13 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 22:08 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 859 | $143.35 | $123,137.65 |
DisclosureSEC source: 0001567619-18-007046 · doc1.xml · nonDerivative · entry 16 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,557 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F14 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.04 to $143.69 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 22:08 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 634 | $142.45 | $90,313.30 |
DisclosureSEC source: 0001567619-18-007046 · doc1.xml · nonDerivative · entry 15 Bilenker Joshua H. · CIK 0001612312 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,416 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F13 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $142.00 to $142.99 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.